News | May 15, 2013

Three Key Questions on Breast-Specific Gamma Imaging for Breast Cancer

Report looks at sensitivity of BSGI for screening and diagnosis of breast cancer

May 15, 2013 — ECRI Institute released a report listing three key questions and the answers concerning breast-specific gamma imaging (BSGI; sometimes referred to as molecular breast imaging or MBI). The technology uses a specially designed gamma camera system to image the uptake of a tracer that emits gamma radiation (most commonly 99mtechnetium-sestamibi [MIBI]). MIBI is preferentially taken up by cancer tissue, and thus BSGI can be used to image breast cancer for a variety of clinical indications. Unlike X-ray mammography, BSGI is not affected by the density of breast tissue, and therefore it may be particularly useful for screening and diagnosis of breast cancer in women with dense breast tissue.

Indications for BSGI may include patients with dense breast tissue, difficult-to-interpret mammograms, implants, palpable lesions not detected by mammography, multiple suspicious or indeterminate lesions, pre-biopsy evaluation of suspect areas, disease staging for breast conservation surgery, and evaluation of post-surgical or post-therapeutic breasts. Contraindications are pregnancy and hypersensitivity to the tracer.

Regulatory Status
All three of the BSGI devices manufactured by Dilon Technologies (Newport News, Va.), Gamma Medica (Northridge, Calif.) and GE Healthcare (Wauwatosa, Wis.) have been cleared by the U.S. Food and Drug Administration (FDA) for marketing under the 510(k) process for diagnostic imaging of the breast as an adjunct to mammography.

State of the Evidence Base
ECRI searched 17 external and internal databases, including PubMed and Embase, through Nov. 7, 2012, for clinical trials on the use of BSGI for breast cancer.

Key Question 1: For what indications and patient populations has BSGI been clinically studied?
ECRI identified published studies of BSGI for screening asymptomatic women, for diagnostic workup, for pretreatment evaluation and for monitoring response to neoadjuvant therapy. They did not identify any published studies of BSGI for monitoring response to post-surgical treatment or for detecting recurrences of cancer.

Key Question 2: What is the accuracy of low-dose BSGI for screening the general population? For screening women with dense breast tissue?
Searches did not identify any studies of low-dose BSGI for screening that met our study inclusion criteria.

Key Question 3: What is the accuracy and utility of BSGI for pre-treatment workup? In comparison to other imaging technologies (such as MRI) for this indication?
Four studies of a total of 445 patients met inclusion criteria for analysis for this question. The crude mean diagnostic yields of occult lesions could be computed from the reported data. They rated the evidence as moderate in quality, but no robust analysis could be performed, and therefore they rated the evidence as insufficient to answer this question. Only one study reported on a direct comparison to MRI. Two studies reported information on the impact of BSGI on medical decision making; the most common impact was triggering additional imaging and biopsies, followed by changes to additional treatment plans or leading to more extensive surgical treatment.                               

ECRI Institute Conclusions
For diagnostic workup, the sensitivity of BSGI for distinguishing between malignant and benign lesions is approximately 92 percent. BSGI may be a valid option for a diagnostic workup in some women, particularly for women with dense breast tissue. However, the evidence available as of November 2012 was insufficient to evaluate the accuracy and utility of BSGI for any other breast screening, diagnostic, or monitoring applications.

For more information: www.ecri.org 

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Breast imaging technologies have seen a rapid evolution.

Breast imaging technologies have seen a rapid evolution.

Feature | Women's Health | June 05, 2018 | By Jeff Zagoudis
Breast imaging technologies have evolved rapidly in the last two decades to help physicians detect breast cancers at
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
Overlay Init